Glaxo had offered a "patient access programme", giving NHS patients free access to Tyverb for the first three months of treatment, but this failed to sway NICE.
Although Britain is only a minor market for Glaxo, the rebuff from the cost-effectiveness agency in its home market is a blow, since Glaxo aims to make Tyverb -- also known as Tykerb or lapatinib -- a key part of its expanding business in cancer.
Decisions from NICE, which has a track record of rejecting a number of other pricey new medicines, are closely followed by governments and healthcare insurers worldwide.
No comments:
Post a Comment